EBV VCA IgG Test

More than 90% of adults have been infected with Epstein-Barr virus, often without ever knowing it. The infection sticks around for life in a quiet, dormant form, and your immune system keeps making antibodies against it forever as proof of that encounter.

VCA IgG (viral capsid antigen immunoglobulin G) is the antibody that confirms you've met this virus. A positive result tells you that EBV (Epstein-Barr virus) is part of your immune history, which matters because the virus has been linked to multiple sclerosis, certain cancers, and several autoimmune conditions. A negative result is rarer in adults and carries its own clinical weight, particularly before transplant or pregnancy.

What This Antibody Actually Is

VCA IgG is a protein your immune system builds in response to the outer shell (capsid) of EBV. Your B cells (a type of white blood cell that makes antibodies) produce it after the virus first infects you, and they keep producing it for the rest of your life. The antibody itself is not the virus. It is a record of the immune response.

Because EBV stays in your body in a dormant state and occasionally reactivates, your VCA IgG level reflects long-term exposure to the virus replicating inside your B cells. Higher levels can suggest that the virus has been more active or that your immune system has been working harder to keep it in check.

Multiple Sclerosis Risk

The link between EBV and multiple sclerosis is one of the strongest virus-disease connections in medicine. In a study of 2,524 people with early multiple sclerosis (MS), 100% were positive for EBV antibodies. Negative EBV serology in someone with MS-like symptoms is so unusual that it should prompt clinicians to consider other neurological diagnoses.

Higher VCA IgG levels track with worse MS-related outcomes. In a study of 100 people with MS, elevated EBV antibody responses were tied to greater disease activity on brain imaging. A separate study of 15,973 people found that higher antibody levels against EBV proteins, including VCAp18, were associated with increased risk of MS, with HLA gene variants influencing the response. In a Sri Lankan study of 107 people, antibody titres above 200 RU/mL were associated with about 11 times the risk of MS compared to lower levels.

Nasopharyngeal Carcinoma

In southern China and other endemic regions, EBV antibody patterns are used to screen for nasopharyngeal carcinoma (a cancer of the upper throat) years before symptoms appear. A prospective study of 512,715 Chinese adults found that plasma EBV markers strongly predicted nasopharyngeal carcinoma occurrence many years before clinical diagnosis.

In a 20-year follow-up of 18,886 people, those whose EBV antibody titres rose over repeated tests had substantially higher cancer risk than those whose titres stayed stable or fell. A cluster-randomized trial of 413,704 people showed that EBV antibody-based screening significantly reduced nasopharyngeal carcinoma mortality over 12 years, particularly in adults aged 50 and older.

Autoimmune Disease Activity

In systemic lupus erythematosus (SLE, an autoimmune disease that can affect skin, joints, kidneys, and other organs), VCA IgG levels behave differently than in healthy people. A study of 232 people with SLE found that higher VCA IgG and IgA levels tracked with greater disease activity, more inflammation, and stronger interferon pathway signaling, all signs of an active autoimmune flare.

In a study of 436 relatives of people with SLE, those whose EBV antibody patterns showed signs of viral reactivation had a higher chance of progressing to clinical SLE themselves. EBV antibodies have also been studied in rheumatoid arthritis, where lower antibody levels appear to track with disease remission.

Cancer Beyond the Nose and Throat

In a southern China cohort of 73,939 people, EBV seropositivity was associated with increased risk of multiple cancers, contributing to a heightened cancer burden in the region. EBV is also tightly linked to classical Hodgkin lymphoma; antibody profiles in 350 people with Hodgkin lymphoma showed distinct elevated responses to VCA proteins in EBV-positive cases.

A nested case-control study of 14,440 Koreans found that higher VCA and EBNA antibody levels were not associated with increased gastric cancer risk in that population, showing that the cancer associations vary by cancer type and geography.

Why a Negative Result Matters Too

If your VCA IgG is negative, you have probably never been exposed to EBV. That sounds like good news, and in most cases it is. But it carries weight in specific situations. Before an organ or stem-cell transplant, an EBV-negative recipient who receives an EBV-positive graft faces higher risk of post-transplant lymphoproliferative disease, a serious complication.

For someone trying to conceive, knowing your EBV status alongside other infections (toxoplasmosis, rubella, CMV, herpes) is part of standard preconception screening. And for an adolescent or young adult who has never been infected, a future first-time exposure carries a higher chance of producing classic mononucleosis symptoms than infection in childhood does.

How to Read Your Result Alongside Other EBV Markers

VCA IgG by itself proves exposure but not timing. The full picture comes from combining it with two other antibodies: VCA IgM (which appears early in infection and fades) and EBNA-1 IgG (Epstein-Barr nuclear antigen, which develops weeks after infection and persists). An evidence-based algorithm using all three correctly classified more than 95% of cases in a series of 1,846 samples.

In a study of 43 people suspected of new EBV infection who had all three antibodies positive, more than half actually had viral reactivation rather than a fresh infection, identified using avidity testing and heterophile antibodies. Pattern matters more than any single value.

What this means for you: a positive VCA IgG with positive EBNA-1 IgG and no IgM is the typical adult finding and usually requires no action. Patterns suggesting active or reactivated infection should be interpreted with EBV DNA testing and clinical context.

Reference Ranges

VCA IgG is reported as positive, negative, or equivocal, with quantitative titres or units that vary by assay. Different commercial platforms (Elecsys, Liaison, Architect, Vidas, Euroimmune) can disagree at the borderline, so a number from one lab does not directly equal a number from another. Standardized clinical thresholds for VCA IgG titre levels above the basic positive cutoff have not been universally established for risk stratification.

These categories are interpretive, not numeric cutpoints, and assay-specific titre values vary widely between labs.

For trending, compare results within the same lab using the same assay over time. A rising titre across repeated samples carries more meaning than any single number, especially in cancer screening contexts where ascending titres predict risk.

When Results Can Be Misleading

VCA IgG is analytically stable. In one evaluation, intra- and inter-assay variability was about 1.6% to 4.8%, meaning the test itself does not produce noisy results. Most variation in interpretation comes from clinical context, not from the lab.

• Assay differences: different lab platforms can disagree at the borderline. A result that is positive on one assay may be equivocal on another, especially near the cutoff.
• Active autoimmune flares: in SLE, VCA IgG levels can rise during disease flares, reflecting EBV reactivation rather than a new infection.
• Specific medications: dimethyl fumarate (a multiple sclerosis drug) lowered VCA IgG starting in the first week of treatment in a study of 17 people. Cyclosporin (an immunosuppressant) caused slight VCA IgG decreases in a randomized study of 49 people with type 1 diabetes. These shifts reflect immune suppression, not a change in EBV status.
• Atypical patterns in young children: in children under 10, isolated VCA IgG can sometimes reflect acute infection rather than past exposure, the opposite of what it usually means in adults.

Acute illness, surgery, recent intense exercise, fasting, BMI, kidney function, and circadian timing have not been shown to meaningfully shift VCA IgG over 24 to 72 hours. This is a marker of long-term immunological history, not a snapshot of your current state.

Tracking Your Trend

For most people, VCA IgG is a one-time confirmatory test. If you are positive, you will stay positive for life, and routine retesting adds little. If you are negative and want to know whether you ever convert (relevant before transplant or for risk research), retesting every few years is reasonable.

Trending matters most in two situations. First, in nasopharyngeal carcinoma screening for high-risk populations or those with family history, ascending titres over repeated tests carry strong predictive value. Second, in autoimmune disease management, rising EBV antibody patterns can correspond to flares. In both cases, comparing values within the same lab and same assay is essential, since cross-platform comparisons can be unreliable.

What to Do With an Abnormal Result

If your VCA IgG is positive and you have no symptoms, no further action is usually needed. EBV is part of nearly everyone's biology. If you have symptoms suggestive of mononucleosis, severe fatigue, or autoimmune disease, the right next step is a full EBV panel (VCA IgM, EBNA-1 IgG, and often EBV DNA testing) to clarify whether the virus is active or reactivated.

If your VCA IgG is negative and you are preparing for transplant, planning a pregnancy, or working in healthcare, share that result with the relevant specialist (transplant team, obstetrician, occupational health). If you have a strong family history of nasopharyngeal carcinoma, particularly with southern Chinese ancestry, consider serial EBV antibody testing alongside an otolaryngologist's evaluation, since rising titres in this group can flag cancer years before symptoms.

If your pattern suggests active or reactivated infection (positive VCA IgM, positive EBV DNA, or rising titres), an infectious disease specialist or immunologist can help interpret the result in your broader clinical context.